中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 6
Jun.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(6): 1358-1361

Research advances in predictive markers for HBeAg seroconversion in chronic hepatitis B patients treated with nucleos( t) ide analogues

DOI: 10.3969/j.issn.1001-5256.2020.06.036

  • Department of Severe Liver Disease,Beijing YouAn Hospital,Capital Medical University

  • Difficult & Complicated Liver Diseases and Artificial Liver Center,Beijing YouAn Hospital,Capital Medical University

  • Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research,Beijing YouAn Hospital,Capital Medical University

Research funding:

 

  • Received Date: 2020-01-15
  • Published Date: 2020-06-20
    Abstract

  • Nucleos( t) ide analogues( NAs) are effective inhibitors for HBV replication and have become the preferred antiviral regimen for most patients with chronic hepatitis B( CHB). HBeAg seroconversion is an important index used to evaluate the durability and efficacy of antiviral therapy in HBeAg-positive CHB patients. The search for biomarkers that can predict HBeAg clearance or seroconversion after NAs treatment plays an important role in the selection of antiviral drugs,the adjustment of treatment regimens,and the achievement of individualized treatment. This article reviews the value of related markers,including HBV DNA,HBV RNA,anti-HBc,and HBcrAg,in predicting HBeAg clearance or seroconversion in CHB patients treated with NAs.

     

    • FullText(HTML)
    • References(43)
  • [1] Polaris Observatory Collaborators. Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol,2018,3(6):383-403.
    [2] Chinese Society of Infectious Diseases,Chinese Medical Association; Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol,2019,35(12):2648-2669.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2648-2669.
    [3] Chinese Society of Infectious Disease,Chinese Society of Hepatology,Chinese Medical Association. The expert consensus on functional cure of chronic hepatitis B[J]. J Clin Hepatol,2019,35(8):1693-1701.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]．临床肝胆病杂志，2019,35(8):1693-1701.
    [4] YUEN MF,CHEN DS,DUSHEIKO GM,et al. Hepatitis B virus infection[J]. Nat Rev Dis Primers,2018,4:18035.
    [5] KOH C,ZHAO X,SAMALA N,et al. AASLD clinical practice guidelines:A critical review of scientific evidence and evolving recommendations[J]. Hepatology,2013,58(6):2142-2152.
    [6] YANG HI,LU SN,LIAW YF,et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma[J]. N Engl J Med,2002,347(3):168-174.
    [7] SHEN J,LIU J,LI C,et al. The prognostic significance of serum HBe Ag on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma:A propensity score matching analysis[J]. J Viral Hepat,2018,25(9):1057-1065.
    [8] WANG JL,DU XF,CHEN SL,et al. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudinebased therapy[J]. World J Gastroenterol,2015,21(32):9598-9606.
    [9] KAYAASLAN B,AKINCI E,ARI A,et al. A long-term multicenter study:Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients[J].Clin Res Hepatol Gastroenterol,2018,42(1):40-47.
    [10] PERRILLO RP,LAI CL,LIAW YF,et al. Predictors of HBe Ag loss after lamivudine treatment for chronic hepatitis B[J].Hepatology,2002,36(1):186-194.
    [11] ZEUZEM S,GANE E,LIAW YF,et al. Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B[J]. J Hepatol,2009,51(1):11-20.
    [12] WONG GL,WONG VW,CHAN HY,et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBe Ag-seroconversion in chronic hepatitis B patients at 3 years[J]. Aliment Pharmacol Ther,2012,35(11):1326-1335.
    [13] PENG CY,HSIEH TC,HSIEH TY,et al. HBV-DNA level at 6months of entecavir treatment predicts HBe Ag loss in HBe Agpositive chronic hepatitis B patients[J]. J Formos Med Assoc,2015,114(4):308-313.
    [14] HUANG YJ,CHANG CS,PENG YC,et al. On-treatment HBV DNA level could predict HBe Ag seroclearance in patients with HBe Ag-positive chronic hepatitis B with entecavir therapy[J]. J Chin Med Assoc,2017,80(6):341-346.
    [15] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.
    [16] TSUGE M,MURAKAMI E,IMAMURA M,et al. Serum HBV RNA and HBe Ag are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J]. J Gastroenterol,2013,48(10):1188-1204.
    [17] GIERSCH K,ALLWEISS L,VOLZ T,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol,2017,66(2):460-462.
    [18] JIA W,ZHU MQ,QI X,et al. Serum hepatitis B virus RNA levels as a predictor of HBe Ag seroconversion during treatment with peginterferon alfa-2a[J]. Virol J,2019,16(1):61.
    [19] van BMMEL F,van BMMEL A,KRAUEL A,et al. Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBe Ag-positive chronic hepatitis B[J]. J Infect Dis,2018,218(7):1066-1074.
    [20] LUO H,ZHANG XX,CAO LH,et al. Serum hepatitis B virus RNA is a predictor of HBe Ag seroconversion and virological response with entecavir treatment in chronic hepatitis B patients[J]. World J Gastroenterol,2019,25(6):719-728.
    [21] van BMMEL F,BARTENS A,MYSICKOVA A,et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology,2015,61(1):66-76.
    [22] YIN XR,SHE GX,HOU JL,et al. Clinical significance and application of quantification of hepatitis B core antibody[J]. J Clin Hepatol,2019,35(10):2156-2158.(in Chinese)尹雪如，佘格欣，侯金林，等．抗-HBc定量的临床意义与应用[J]．临床肝胆病杂志，2019,35(10):2156-2158.
    [23] LI MR,LU JH,YE LH,et al. Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatmentnave chronic hepatitis B patients[J]. Medicine(Baltimore),2016,95(34):e4422.
    [24] LI MR,ZHENG HW,LU JH,et al. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatmentnave patients with chronic hepatitis B[J]. Oncotarget,2017,8(7):11063-11070.
    [25] FAN R,SUN J,YUAN Q,et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut,2016,65(2):313-320.
    [26] CAI S,LI Z,YU T,et al. Serum hepatitis B core antibody levels predict HBe Ag seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs[J]. Infect Drug Resist,2018,11:469-477.
    [27] SARIN SK,KUMAR M,LAU GK,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int,2016,10(1):1-98.
    [28] XU JH,SONG LW,LI N,et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir[J]. J Viral Hepat,2017,24(2):148-154.
    [29] ZOULIM F,CAROSI G,GREENBLOOM S,et al. Quantification of HBs Ag in nucleos(t)ide-nave patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study[J]. J Hepatol,2015,62(1):56-63.
    [30] CHEN CH,LU SN,HUNG CH,et al. The role of hepatitis B surface antigen quantification in predicting HBs Ag loss and HBV relapse after discontinuation of lamivudine treatment[J].J Hepatol,2014,61(3):515-522.
    [31] KIM GA,LIM YS,AN J,et al. HBs Ag seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B:Clinical outcomes and durability[J]. Gut,2014,63(8):1325-1332.
    [32] YANG J,CHEN J,YE P,et al. HBs Ag as an important predictor of HBe Ag seroconversion following antiviral treatment for HBe Ag-positive chronic hepatitis B patients[J]. J Transl Med,2014,12:183.
    [33] SINGH AK,SHARMA MK,HISSAR SS,et al. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment[J]. J Viral Hepat,2014,21(6):439-446.
    [34] MAK LY,WONG DK,CHEUNG KS,et al. Review article:Hepatitis B core-related antigen(HBcrAg):An emerging marker for chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2018,47(1):43-54.
    [35] WONG DK,SETO WK,CHEUNG KS,et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA[J]. Liver Int,2017,37(7):995-1001.
    [36] CHEN EQ,TANG H. Hepatitis B virus core-related antigen:A promising new serum marker for hepatitis B virus[J]. J Clin Hepatol,2019,35(10):2159-2162.(in Chinese)陈恩强，唐红．一种有前途的新型HBV血清标志物———HBcrAg[J]．临床肝胆病杂志，2019,35(10):2159-2162.
    [37] WANG ML,LIAO J,WEI B,et al. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBe Ag seroconversion in chronic hepatitis B patients with pegylated interferon therapy[J]. Infect Dis(Lond),2018,50(7):522-530.
    [38] WANG B,CAREY I,BRUCE M,et al. HBsAg and HBcrAg as predictors of HBe Ag seroconversion in HBe Ag-positive patients treated with nucleos(t)ide analogues[J]. J Viral Hepat,2018,25(8):886-893.
    [39] LI C,JI H,CAI Y,et al. Serum interleukin-37 concentrations and HBe Ag seroconversion in chronic HBV patients during telbivudine treatment[J]. J Interferon Cytokine Res,2013,33(10):612-618.
    [40] GUO R,MAO H,HU X,et al. Slow reduction of IP-10 Levels predicts HBe Ag seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment[J]. Sci Rep,2016,6:37015.
    [41] MA SW,HUANG X,LI YY,et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBe Ag seroconversion in chronic hepatitis B[J]. J Hepatol,2012,56(4):775-781.
    [42] ZHENG Q,ZHU YY,CHEN J,et al. Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBe Ag loss[J]. J Viral Hepat,2014,21(12):909-916.
    [43] European Association for the Study of the Liver. EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.
    • Relative Articles

  • Relative Articles

    [1]Lili GAO, Yong WANG, Huafang YAN, Xiaoliang WANG, Yunfeng WANG. Characteristics of cardiometabolic risk in patients with different subtypes of non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2025, 41(1): 63-68. doi: 10.12449/JCH250110
    [2]Journal of Hepatology｜Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer[J]. Journal of Clinical Hepatology, 2024, 40(9): 1872-1872. doi: 10.12449/JCH2409.gwqkjpwzjj3
    [3]Shuyang ZHANG, Yanzhen BI, Shousheng LIU, Sheng LIU, Yongning XIN. Differentially expressed microRNAs in plasma exosomes from patients with chronic hepatitis B or hepatitis B virus-related acute-on-chronic liver failure: A bioinformatics analysis[J]. Journal of Clinical Hepatology, 2023, 39(8): 1848-1856. doi: 10.3969/j.issn.1001-5256.2023.08.013
    [4]Xiaodong ZHOU, Na TIAN, Minghua ZHENG. Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2336-2339. doi: 10.3969/j.issn.1001-5256.2023.10.010
    [5]Dongna ZHAO, Qian LIU, Huijie LIANG, Haozhe CUI, Lingqun MENG, Huiliang E, Liying CAO. Effect of ideal cardiovascular health metrics on the incidence rate of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 124-128. doi: 10.3969/j.issn.1001-5256.2022.01.019
    [6]Zhihua ZUO, Chuyi ZENG, Yao JIANG, Hualin TAO, Yongcan GUO. Regulatory role of long non-coding RNAs in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1704-1707. doi: 10.3969/j.issn.1001-5256.2021.07.048
    [7]Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
    [8]Luying ZHU, Yuchen LI, Lihua DENG, Jingtong WANG. Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2215-2219. doi: 10.3969/j.issn.1001-5256.2021.09.043
    [9]Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
    [10]Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
    [11]Zhang ShiLong, Peng CiJun, Feng ZanJie, Gao WeiDong, Duan YuLing, Fan GuoXin. Mechanism of action of microRNA in the regulation of hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2019, 35(7): 1629-1631. doi: 10.3969/j.issn.1001-5256.2019.07.045
    [12]Mai JingYin, Chen TianYang, Cheng Yang. Changes in microRNA expression profile in the liver of mice with nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2017, 33(12): 2372-2375. doi: 10.3969/j.issn.1001-5256.2017.12.023
    [13]Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
    [14]Zhang LiFen, Yu HongYu. Role of circulating microRNAs in development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(10): 2001-2003. doi: 10.3969/j.issn.1001-5256.2016.10.042
    [15]Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
    [16]Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
    [17]Li Qiang, Zhuo QiBin, Chen Liang, Huang YuXian. Research advances in association between non- alcoholic fatty liver disease and cardiovascular disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1046-1049. doi: 10.3969/j.issn.1001-5256.2015.07.012
    [18]Peng XiaoFang, Liu HaiYing. Research advances in circulating miRNAs for diagnosis of hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2014, 30(9): 965-968. doi: 10.3969/j.issn.1001-5256.2014.09.032
    [19]Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
    [20]Li JiangBin, Du XiLin, Dong Rui, Yin JiKai, Lu JianGuo. Incidence and prevention of liver transplantation- related cardiovascular complications[J]. Journal of Clinical Hepatology, 2014, 30(1): 75-77. doi: 10.3969/j.issn.1001-5256.2014.01.022
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(3)

    1. 王阁，赵越超，律广富，徐岩，黄晓巍，林喆. miRNA在心血管疾病中的研究进展. 人参研究. 2023(04): 51-55 .
    2. 刘涛，赵洋，周恩涛，杨忠路，贺元辰，刘方绪，卜泽. 心肌梗死患者微小RNA表达及其与肌钙蛋白T相关性研究. 创伤与急危重病医学. 2022(03): 170-173 .
    3. 张小建，张军毅，冯嵩，李丹. 病毒性心肌炎患儿血清IL-35、miR-155和SAA的表达及临床意义. 分子诊断与治疗杂志. 2022(06): 1048-1051 .

    Other cited types(0)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (818) PDF downloads(111) Cited by(3)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2183]YesterdayPV[4802]TodayIP[123]TodayPV[243]Online[14]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return